Vaccine building 'kit': combining peptide bricks to elicit a desired immune response without adding an adjuvant.
Aleksandr A GorbunovEvgeniia P SannikovaIrek I GubaidullinGayane A SerobyanAlina Yu GorbunovaAnna V SerkinaKonstantin S PlokhikhRoman A KamyshinskyMikhail F VorovitchNatalia V BulushovaSergei KuchinDmitry G KozlovPublished in: Nanomedicine (London, England) (2022)
Protein nanoparticles (NPs) can be used as vaccine platforms for target antigen presentation. Aim: To conduct a proof-of-concept study to demonstrate that an effective NP platform can be built based on a short self-assembling peptide (SAP) rather than a large self-assembling protein. Materials & methods: SUMO-based protein fusions (SFs) containing an N-terminal SAP and a C-terminal antigen were designed, expressed in Escherichia coli and purified. The structure was investigated by electron microscopy. The antibody response was tested in mice after two adjuvant-free immunizations. Results: Renatured SFs form fiber-like NPs with the antigen exposed on the surface and induce a significant antibody response with a remarkably high target-to-platform ratio. Conclusion: The platform is effective and has considerable potential for modification toward various applications, including vaccine development.
Keyphrases
- escherichia coli
- immune response
- high throughput
- early stage
- electron microscopy
- protein protein
- amino acid
- binding protein
- adipose tissue
- mass spectrometry
- cystic fibrosis
- climate change
- high resolution
- metabolic syndrome
- toll like receptor
- high fat diet induced
- staphylococcus aureus
- multidrug resistant
- skeletal muscle
- risk assessment
- biofilm formation
- candida albicans